ArticleOncotarget2014
Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 37 citations in OpenAlex.
- Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma.Pharmaceutics · 2024Article
- Nucleolin promotes angiogenesis and endothelial metabolism along the oncofetal axis in the human brain vasculature.JCI insight · 2023Article
- Review
- Optimization of Tumor Targeting Gold Nanoparticles for Glioblastoma Applications.Nanomaterials (Basel, Switzerland) · 2022Article
- Using ELP Repeats as a Scaffold for De Novo Construction of Gadolinium-Binding Domains within Multifunctional Recombinant Proteins for Targeted Delivery of Gadolinium to Tumour Cells.International journal of molecular sciences · 2022Article
- Aptamer-Based In Vivo Therapeutic Targeting of Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
- Growth Factor Midkine Aggravates Pulmonary Arterial Hypertension via Surface Nucleolin.Scientific reports · 2020Article
- Investigation of Different Molecular Weight Fucoidan Fractions Derived from New ZealandMarine drugs · 2018Article
- Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies.Scientific reports · 2018Article
- MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.Molecular neurobiology · 2018Article
- Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.Cell death & disease · 2018Article
- Resetting cancer stem cell regulatory nodes upon MYC inhibition.EMBO reports · 2016Article
- Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.Oncotarget · 2016Article
- MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-β1.Oncotarget · 2016Article
- AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin.PloS one · 2016Article
- Article
- Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.Molecular oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The three oncogenes, ErbB receptors, Ras proteins and nucleolin may contribute to malignant transformation. Previously, we demonstrated that nucleolin could bind both Ras protein and ErbB receptors. We also showed that the crosstalk between the three proteins facilitates anchorage independent growth and tumor growth in nude mice, and that inhibition of this interaction in prostate and colon cancer cells reduces tumorigenicity. In the present study, we show that treatment with Ras and nucleolin inhibitors reduces the oncogenic effect induced by ErbB1 receptor in U87-MG cells. This combined treatment enhances cell death, reduces cell proliferation and cell migration. Moreover, we demonstrate a pivotal role of nucleolin in ErbB1 activation by its ligand. Nucleolin inhibitor prevents EGF-induced receptor activation and its downstream signaling followed by reduced proliferation. Furthermore, inhibition of Ras by Salirasib (FTS), mainly reduces cell viability and motility. The combined treatment, which targets both Ras and nucleolin, additively reduces tumorigenicity both in vitro and in vivo. These results suggest that targeting both nucleolin and Ras may represent an additional opportunity for inhibiting cancers, including glioblastoma, that are driven by these oncogenes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.